title: Positron emission tomography/computed tomography in melanoma.
abstract: Fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) has been invaluable in the assessment of melanoma throughout the course of the disease. As with any modality, the studies are incomplete and more information will be gleaned as our experience progresses. Additionally, it is hoped that a newer PET agent in the pipeline will give us even greater success in the identification and subsequent treatment of melanoma. This article aims to examine the utilization of PET/CT in the staging, prognostication, and follow-up of melanoma while providing the physicians who order and interpret these studies practical guidelines and interpretive pitfalls.
authors.affiliation: University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA.
authors.forename: Austin C
authors.initials: AC
authors.lastname: Bourgeois
authors.forename: Ted T
authors.initials: TT
authors.lastname: Chang
authors.forename: Lindsay M
authors.initials: LM
authors.lastname: Fish
authors.forename: Yong C
authors.initials: YC
authors.lastname: Bradley
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000473:pathology; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D009367:Neoplasm Staging; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: CT; Cutaneous melanoma; Melanoma; PET